Mitoxantrone in the Treatment of Acute Leukemia
Mitoxantrone is an anthracenedione with structural similarities to doxorubicin . Preclinical studies showed activity against a variety of experimental mouse leukemias both in vitro and in vivo, including partial activity against a subline of P388 leukemia resistant to doxorubicin [2–4]. Clinical trials with mitoxantrone in patients with relapsed and/or refractory acute leukemia have shown activity close to that seen with the anthracycline antibodies with a lower incidence of side effects [5–11]. In previously untreated patients with acute lymphatic leukemia (ALL) and acute nonlymphatic leukemia (ANLL), mitoxantrone has shown promise as a frontline treatment [11–14] or in combination with other chemotherapy agents in refractory leukemia [15–17].
KeywordsAcute Myeloid Leukemia Eastern Cooperative Oncology Group Acute Leukemia Acute Lymphatic Leukemia P388 Leukemia
Unable to display preview. Download preview PDF.
- 1.Zee-Cheng RKY, Cheng CC (1978) Antineoplastic agents. Structure-activity relationship study of bis (substituted amino-alkylamino) anthraquinones. J Med Chem 21: 291–294Google Scholar
- 12.Van Echo DA, Schulman PN, Ferrari A, Budman D, Markus SD, Wiernik PH (1982) A phase II trial of mitoxantrone (DHAD.NSC 301739) in adult acute leukemia. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1: 132 (abstr)Google Scholar
- 17.Hiddemann W, Kreutzmann H, Staif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder EV, Arlin Z, Büchner T (1987) High-dose cytosine-arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14: 73–77PubMedGoogle Scholar